NCT00842803

Brief Summary

The purpose of the study is to examine if outcome after liver transplantation is improved by using albumin infusion post-transplantation.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jan 2010

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 11, 2009

Completed
1 day until next milestone

First Posted

Study publicly available on registry

February 12, 2009

Completed
11 months until next milestone

Study Start

First participant enrolled

January 1, 2010

Completed
2.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2012

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2012

Completed
Last Updated

September 18, 2009

Status Verified

September 1, 2009

Enrollment Period

2.4 years

First QC Date

February 11, 2009

Last Update Submit

September 17, 2009

Conditions

Keywords

LivertransplantalbuminoutcomeLiver transplant recipients canadian transplant status 1 or 2

Outcome Measures

Primary Outcomes (1)

  • Post Transplant Liver Function Test (PTLFT)

    Post-operative Day1 through 7 and Day 15,30, 45

Secondary Outcomes (11)

  • Functional 6 minutes walking test

    Post-operative

  • Calculated creatinine clearance

    Post-operative day 1, 7, 15, 30, 45

  • Length of hospital stay

    post-operative

  • ICU length of stay

    post-operative

  • duration of mechanical ventilation

    post-operative

  • +6 more secondary outcomes

Study Arms (2)

Control Group

NO INTERVENTION

Patients in this group will not be allowed albumin or any other colloids fluid for the first 7 days post-operative

Albumin group

EXPERIMENTAL

Patients in this arm will receive albumin infusions 3 times a day for the first 7 days post-operative

Drug: Albumin infusion (25% albumin)

Interventions

Patients in this arm will receive albumin infusions 3 times a day for the first 7 days post-operative

Albumin group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • years or older
  • Canadian Transplant status 1 or 2
  • Patients at the Royal Victoria Hospital, Montreal, Canada

You may not qualify if:

  • Emergency liver transplant (canadian transplant status 3 or 4)
  • patients who have received more than 300cc of albumin within 48 hours prior to transplant
  • patients who underwent previous solid organ transplant
  • multi-organs transplant recipients
  • patients who had previous adverse reaction to human albumin solution
  • patients who have religious restriction to receiving human blood products.
  • patients or surrogate unable to give consent to the study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Royal Victoria Hospital

Montreal, Quebec, H3A1A1, Canada

Location

MeSH Terms

Interventions

Albumins

Intervention Hierarchy (Ancestors)

ProteinsAmino Acids, Peptides, and Proteins

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

February 11, 2009

First Posted

February 12, 2009

Study Start

January 1, 2010

Primary Completion

June 1, 2012

Study Completion

June 1, 2012

Last Updated

September 18, 2009

Record last verified: 2009-09

Locations